Coadministration of excess rucaparib, to block the NAD+ binding pocket in the PARP enzymes, significantly reduced tumor uptake (P < 0.05; Fig. 4D), which was confirmed by autoradiography (Fig. 4E). This evidence concerns the gene PARP1 and neoplasm.